These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 17881149)

  • 21. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
    Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
    Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx.
    Rivera F; Vega-Villegas ME; López-Brea MF; García-Castaño A; de Juan A; Collado A; Galdós P; Rubio A; del Valle A; Rama J; Sanz-Ortiz J
    Laryngoscope; 2004 Jul; 114(7):1163-9. PubMed ID: 15235341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.
    Byström P; Frödin JE; Berglund A; Wilking N; Glimelius B
    Radiother Oncol; 2004 Feb; 70(2):171-5. PubMed ID: 15028404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.
    Atasoy BM; Abacioglu U; Dane F; Ozgen Z; Yumuk PF; Ozden S; Akgun Z; Mayadagli A; Basaran G; Turhal S; Sengoz M
    J BUON; 2007; 12(2):203-8. PubMed ID: 17600873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up.
    Fernández-Martos C; Aparicio J; Bosch C; Torregrosa M; Campos JM; Garcera S; Vicent JM; Maestu I; Climent MA; Mengual JL; Tormo A; Hernandez A; Estevan R; Richart JM; Viciano V; Uribe N; Campos J; Puchades R; Arlandis F; Almenar D
    J Clin Oncol; 2004 Aug; 22(15):3016-22. PubMed ID: 15210740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
    Arnold SM; Regine WF; Ahmed MM; Valentino J; Spring P; Kudrimoti M; Kenady D; Desimone P; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1411-7. PubMed ID: 15050317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.
    Chougule P; Wanebo H; Akerley W; McRae R; Nigri P; Leone L; Safran H; Ready N; Koness RJ; Radie-Keane K; Cole B
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-57-S19-61. PubMed ID: 9427268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
    Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study.
    Endo M; Takada Y; Obayashi K; Kotani Y; Satouchi M; Kado T; Sugimura K
    Radiat Med; 2005 Aug; 23(5):331-5. PubMed ID: 16342905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Imai H; Utsugi M; Shimizu Y; Iijima H; Tomizawa Y; Hisada T; Ishizuka T; Saito R; Mori M
    Anticancer Drugs; 2007 Apr; 18(4):471-6. PubMed ID: 17351400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
    Pfeiffer P
    Acta Oncol; 2005; 44(3):224-9. PubMed ID: 16076693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
    Jatoi A; Martenson JA; Foster NR; McLeod HL; Lair BS; Nichols F; Tschetter LK; Moore DF; Fitch TR; Alberts SR;
    Am J Clin Oncol; 2007 Oct; 30(5):507-13. PubMed ID: 17921712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.